Cargando…
Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
PURPOSE: Early diagnosis of cancer is critical for improving patient outcomes, but cancers may be hard to diagnose if patients present with nonspecific signs and symptoms. We have previously shown that nuclear magnetic resonance (NMR) metabolomics analysis can detect cancer in animal models and dist...
Autores principales: | Larkin, James R., Anthony, Susan, Johanssen, Vanessa A., Yeo, Tianrong, Sealey, Megan, Yates, Abi G., Smith, Claire Friedemann, Claridge, Timothy D.W., Nicholson, Brian D., Moreland, Julie-Ann, Gleeson, Fergus, Sibson, Nicola R., Anthony, Daniel C., Probert, Fay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7613224/ https://www.ncbi.nlm.nih.gov/pubmed/34983789 http://dx.doi.org/10.1158/1078-0432.CCR-21-2855 |
Ejemplares similares
-
Classifying the antibody-negative NMO syndromes: Clinical, imaging, and metabolomic modeling
por: Yeo, Tianrong, et al.
Publicado: (2019) -
Integrative biochemical, proteomics and metabolomics cerebrospinal fluid biomarkers predict clinical conversion to multiple sclerosis
por: Probert, Fay, et al.
Publicado: (2021) -
A blood-based metabolomics test to distinguish relapsing–remitting and secondary progressive multiple sclerosis: addressing practical considerations for clinical application
por: Yeo, Tianrong, et al.
Publicado: (2020) -
Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model
por: Yeo, Tianrong, et al.
Publicado: (2022) -
Objective biomarkers for clinical relapse in multiple sclerosis: a metabolomics approach
por: Yeo, Tianrong, et al.
Publicado: (2021)